MetaCap

Rhythm Pharmaceuticals (RYTM) vs Summit Therapeutics (SMMT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Rhythm Pharmaceuticals (RYTM) has outperformed Summit Therapeutics (SMMT) over the past year, gaining 10.4% versus a loss of 38.5%. Over five years, RYTM leads with a +1116.0% price change compared with +92.8% for SMMT. Summit Therapeutics is the larger company by market cap ($7.96 billion vs $7.79 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RYTM+10.44%SMMT-38.54%
+68%+12%-44%
Nov 21, 20251 yearNov 20, 2026
RYTM+990.87%SMMT+85.98%
+1078%+469%-141%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RYTM versus SMMT key metrics
MetricRYTMSMMT
Share price$112.36$9.95
Market cap$7.79B$7.96B
1-day change-3.80%-5.87%
YTD return+4.97%-43.11%
1-year return+10.44%-38.54%
5-year return+1116.02%+92.83%
EPS (TTM)$-2.91$-1.06
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$189.76M—
Revenue growth (YoY)+45.83%—
Net income (latest FY)$-196.54M$-1.08B
Gross margin89.73%—
Operating margin-101.19%—
Net margin-103.57%—
52-week high$122.20$29.23
52-week low$74.50$9.89
Distance from 52-week high-8.05%-65.96%
Analyst consensusstrong_buybuy
Avg. price target upside+24.71%+189.15%
Average volume1.10M6.68M
Shares outstanding69.33M799.76M
Employees414265
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RYTM has outperformed SMMT by 49.0 percentage points over the past year.

About Rhythm Pharmaceuticals

RYTM stock →

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.

Health Care · Biotechnology: Pharmaceutical Preparations · 414 employees

About Summit Therapeutics

SMMT stock →

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).

Health Care · Biotechnology: Pharmaceutical Preparations · 265 employees

RYTM vs SMMT FAQ

Which is bigger, Rhythm Pharmaceuticals or Summit Therapeutics?

Summit Therapeutics (SMMT) is larger, with a market capitalization of $7.96B compared with $7.79B for Rhythm Pharmaceuticals (RYTM).

Which stock has performed better over the past year, RYTM or SMMT?

RYTM returned +10.44% over the past 12 months, compared with -38.54% for SMMT (price return, excluding dividends). Past performance does not predict future results.

Are Rhythm Pharmaceuticals and Summit Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons